Quarterly ResultMay 14, 2026, 04:28 PM
VolitionRx Q1 Net Loss $6.7M; Going Concern Doubt Remains
AI Summary
VolitionRx reported a net loss of $6.7 million for the first quarter of 2026, an increase from $5.5 million in the prior year, despite total revenues significantly rising to $985,076. The company's auditors continue to express substantial doubt about its ability to continue as a going concern. Subsequent to the quarter, VolitionRx completed a one-for-twenty reverse stock split and raised approximately $0.6 million through common stock sales.
Key Highlights
- Substantial doubt about VolitionRx's ability to continue as a going concern remains.
- Q1 2026 net loss increased to $6.7 million from $5.5 million in Q1 2025.
- Total revenues for Q1 2026 surged to $985,076 from $246,385 year-over-year.
- Product revenue significantly increased to $926,127 in Q1 2026 from $130,909.
- Operating loss slightly improved to $(5.3) million from $(5.5) million year-over-year.
- Loss per common share was $(0.97) in Q1 2026, an improvement from $(1.12) in Q1 2025.
- Cash and cash equivalents stood at $3.1 million as of March 31, 2026.
- Company completed a one-for-twenty reverse stock split in April 2026.